研究実績
(2023〜)
| 20. Matsuda K, Kariya R, Maeda K, Okada S. Viruses. Evaluating the Use of Sacran, a Polysaccharide Isolated from Aphanothece sacrum, as a Possible Microbicide for Preventing HIV-1 Infection. Viruses. 16(9):1501, 2024. |
| 19. Yamamoto S, Matsuda K, Maeda K, Mizoue T, Horii K, Okudera K, Tan T, Oshiro Y, Inamura N, Nemoto T, S Takeuchi J, Konishi M, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N. Protection of Omicron Bivalent Vaccine, Previous Infection, and Their Induced Neutralizing Antibodies Against Symptomatic Infection With Omicron XBB.1.16 and EG.5.1. Open Forum Infect Dis. 10(9):ofae519, 2024. |
| 18. Iwamoto N, Takamatsu Y, Asai Y, Tsuchiya K, Matsuda K, Oshiro Y, Inamura N, Terada M, Nemoto T, Kimura M, Saito S, Morioka S, Maeda K, Mitsuya H, Ohmagari N. High diagnostic accuracy of quantitative SARS-CoV-2 spike-binding-IgG assay and correlation with in vitro viral neutralizing activity. Heliyon. 10(2):e24513, 2024. |
| 17. Reda O, Monde K, Sugata K, Rahman A, Sakhor W, Rajib SA, Sithi SN, Tan BJY, Niimura K, Motozono C, Maeda K, Ono M, Takeuchi H, Satou Y. HIV-Tocky system to visualize proviral expression dynamics. Commun Biol. 7(1):344, 2024. |
| 16. Ishii T, Kobayakawa T, Matsuda K, Nigorikawa K, Bolah P, Noborio A, Tsuji K, Ohashi N, Yoshimura K, Nomura W, Mitsuya H, Maeda K, Tamamura H. Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents. ACS Infect Dis. 10(6):2250-2261, 2024. |
| 15. Matsuda K and Maeda K. HIV Reservoirs and Treatment Strategies toward Curing HIV Infection. Int. J. Mol. Sci. 25(5), 2621, 2024. |
| 14. Tsuchiya K, Maeda K, Matsuda K, Takamatsu Y, Kinoshita N, Kutsuna S, Hayashida T, Gatanaga H, Ohmagari N, Oka S, Mitsuya H. Neutralization activity of IgG antibody in COVID 19 convalescent plasma against SARS-CoV-2 variants. Sci Rep. 13(1):1263, 2023. |
| 13. Kitamura H*, Sukegawa S*, Matsuda K*, Tanimoto K, Kobayakawa T, Takahashi K, Tamamura H, Tsuchiya K, Gatanaga H, Maeda K, Takeuchi H. 4-phenylquinoline-8-amine induces HIV-1 reactivation and apoptosis in latently HIV-1 infected cells. Biochem Biophys Res Commun. 641:139-147, 2023. (* co-first author) |
| 12. Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, Inamura N, Takeuchi JS, Konishi M, Ozeki M, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave. Int J Infect Dis. 128:347-354, 2023. |
| 11. Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H. Identification of SARS-CoV-2 Mpro inhibitors containing P1′ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nat Commun. 14(1):1076, 2023. |
| 10. Terada-Hirashima J, Takamatsu Y, Shimizu Y, Uemura Y, Takeuchi JS, Tomita N, Matsuda K, Maeda K, Yamamoto S, Fukunaga A, Ohmagari N, Mikami A, Sonoda K, Ujiie M, Mitsuya H, Sugiura W. Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label,single-senter, non-randomized, controlled study in Japan. Hum Vaccin Immunother. 19(1):2193074, 2023. |
| 9. Yamamoto S, Matsuda K, Maeda K, Oshiro Y, Inamura N, Mizoue T, Konishi M, Takeuchi JS, Horii K, Ozeki M, Sugiyama H, Mitsuya H, Sugiura W, Ohmagari N. Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2. BMC Infect Dis. 23(1):282, 2023. |
| 8. Ishii T, Kobayakawa T, Matsuda K, Tsuji K, Ohashi N, Nakahata S, Noborio A, Yoshimura K, Mitsuya H, Maeda K, and Tamamura H. Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity. Eur. J. Med. Chem. 256:115449, 2023. |
| 7. Amano M, Ichikawa Y, Uemura Y, Matsumoto S, Maeda K, Matsushita S, Shimada S, Mitsuya H. Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines. J Infect. 86(5):e130-e132, 2023. |
| 6. Inada M, Togano T, Terada M, Shiratori K, Tsuzuki S, Takamatsu Y, Saito S, Hangaishi A, Morioka S, Kutsuna S, Maeda K, Mitsuya H, Ohmagari N. Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma. Transfus Apher Sci. 62(3):103638, 2023. |
| 5. Matsuda K*, Tan BJY, Rajib SA, Tsuchiya K, Satou Y*, Maeda K*. Assessing the effects of ART-LRA combination therapy on eradicating replication-competent HIV provirus in a Jurkat cell culture model. STAR Protocols. 4(4):102547, 2023. (* co-corresponding author) |
| 4. Yamamoto S*, Matsuda K*, Maeda K, Okudera K, Oshiro Y, Inamura N, Nemoto T, Takeuchi JS, Li Y, Konishi M, Tsuchiya K, Gatanaga H, Oka S, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Pre-infection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: a propensity score-matched analysis. J Infect Dis. 228:1652-61, 2023. (* co-first author) |
| 3. Saito S, Kutsuna S, Akifumi I, Hase R, Oda R, Terada J, Shimizu Y, Uemura Y, Takamatsu Y, Yasuhara A, Shiratori K, Satake M, Sakamoto N, Miyazaki Y, Shimizu H, Togano T, Matsunaga A, Okuma K, Hamaguchi I, Fujisawa K, Nagashima M, Ashida S, Terada M, Kimura A, Morioka S, Matsubayashi K, Tsuno NH, Kojima M, Kuramitsu M, Tezuka K, Ikebe E, Ishizaka Y, Maeda K, Hangaishi A, Mikami A, Sugiura W, Ohmagari N, Mitsuya H. Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial. J Infect Chemother. 29:869-74, 2023. |
| 2. Suzuki T, Asai Y, Kozue Takahashi K, Sanada M, Shimanishi Y, Terada M, Sato L, Inada M, Yamada G, Akiyama Y, Oshiro Y, Shiratori K, Togano T, Takamatsu Y, Maeda K, Matsunaga A, Ishizaka Y, Nomoto H, Iwamoto N, Saito S, Kutsuna S, Morioka S, Ohmagari N. Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved. Heliyon. 9 (2023) e20568, 2023. |
| 1. Terada M, Saito S, Kutsuna S, Kinoshita-Iwamoto N, Togano T, Hangaishi A, Shiratori K, Takamatsu Y, Maeda K, Ishizaka Y, Ohtsu H, Satake M, Mitsuya H, Ohmagari N. Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals. Life (Basel). 13(11):2184, 2023. |
(〜2022, Selected)
| 1. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. N Engl J Med. NEJMc2119407, 2022. |
| 2. Yamamoto S, Fukunaga A, Tanaka A, Takeuchi JS, Inoue Y, Kimura M, Maeda K, Ueda G, Mizoue T, Ujiie M, Sugiura W, Ohmagari N. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. Vaccine. 40(13):1924-1927, 2022. |
| 3. Beppu H, Ogawa T, Ishikane M, Kawanishi T, Fukuda T, Sato L, Matsunaga A, Maeda K, Katagiri D, Ishizaka Y, Mitsuya H, Ohmagari N, Yasui F, Kohara M, Kikuchi K, Wakai S. A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection. CEN Case Rep. 1-6, 2022. |
| 4. Inada M, Ishikane M, Terada M, Matsunaga A, Maeda K, Iwamoto N, Ujiie M, Kutsuna S, Morioka S, Ishizaka Y, Mitsuya H, Ohmagari N. Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection. Int J Infect Dis. 119:18-20, 2022. |
| 5. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med. 386(15):1475-1477, 2022. |
| 6. Miyazato Y, Yamamoto K, Nakaya Y, Morioka S, Takeuchi JS, Takamatsu Y, Maeda K, Kimura M, Sugiura W, Mitsuya H, Yano M, Ohmagari N. Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19. J Infect Chemother. 28:991-994, 2022. |
| 7. Yamamoto S, Maeda K, Matsuda K, Tanaka A, Horii K, Okudera K, Takeuchi JS, Mizoue T, Konishi M, Ozeki M, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study. Clin Infect Dis. 75: e683-91, 2022. |
| 8. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team, Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature. 607, 119-127, 2022. |
| 9. Amano M, Maeda K, Tsuchiya K, Shimada S, Mitsuya H. Third-dose BNT162b2 vaccination elicits markedly high-level SARS-CoV-2-neutralizing antibodies in vaccinees who poorly responded to second dose in Japan. J Infect Dis. 226:2038-39, 2022. |
| 10. Khor SS, Omae Y, Takeuchi JS, Fukunaga A, Yamamoto S, Tanaka A, Matsuda K, Kimura M, Maeda K, Ueda G, Mizoue T, Ujiie M, Mitsuya H, Ohmagari N, Sugiura W, Tokunaga K. An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine. Vaccines (Basel). 10(4):563, 2022. |
| 11. Tomita N, Saito S, Terada-Hirashima J, Mikami A, Uemura Y, Kutsuna S, Nomoto H, Fujisawa K, Nagashima M, Terada M, Ashida S, Morioka S, Satake M, Hangaishi A, Togano T, Shiratori K, Takamatsu Y, Maeda K, Ohmagari N, Sugiura W, Mitsuya H. A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). Life (Basel). 2022 Jun 8; 12(6):856, 2022. |
| 12. Terayama Y, Tomita N, Terada-Hirashima J, Uemura Y, Shimizu Y, Takeuchi JS, Takamatsu Y, Maeda K, Mikami A, Ujiie M, Sugiura W. Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA). Life (Basel). 12(7):966, 2022. |
| 13. Amano M, Otsu S, Maeda K, Uemura Y, Shimizu Y, Omata K, Matsuoka M, Shimada S, Mitsuya H. Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants. Sci Rep. 12(1):13524, 2022. |
| 14. Takeuchi JS, Fukunaga A, Yamamoto S, Tanaka A, Matsuda K, Kimura M, Kamikawa A, Kito Y, Maeda K, Ueda G, Mizoue T, Ujiie M, Mitsuya H, Ohmagari N, Sugiura W. SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. Sci Rep. 12(1):15447, 2022. |
| 15. Takamatsu Y, Omata K, Shimizu Y, Kinoshita-Iwamoto N, Terada M, Suzuki T, Morioka S, Uemura Y, Ohmagari N, Maeda K, Mitsuya H. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response. Microbiol Spectr. 10:e0271622, 2022. |
| 16. Okumura N, Saito S, Takamatsu Y, Takeuchi JS, Asai Y, Sanada M, Iwamoto N, Maeda K, Mitsuya H, Ohmagari N. Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination. J Infect Chemother. 28(12):1704-1706, 2022. |
| 17. Hayashi Y, Matsuda K, Tanigawa K, Tanikawa T, Maeda K, Tsuchiya K. Dihydroceramide Δ4-Desaturase 1 Is Not Involved in SARS-CoV-2 Infection. Biol Pharm Bull. 45(10):1559-1563, 2022. |
| 18. Matsuda K, Islam S, Takada T, Tsuchiya K, Yang BTJ, Shin-ichiro Hattori SI, Katsuya H, Kitagawa K, Kim KS, Matsuo M, Sugata K, Delino NS, Gatanaga H, Yoshimura K, Matsushita S, Mitsuya H, Iwami S, Satou Y, and Maeda K. A widely-distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro. Cell Rep. Methods 1, 100122, 2021. |
| 19. Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, Koga M, Mitamura K, Yagi K, Maeda K, Kato H, Nojima M, Pattinson D, Ogura T, Baba R, Fujita K, Nagai H, Yamamoto S, Saito M, Adachi E, Ochi J, Hattori SI, Suzuki T, Miyazato Y, Chiba S, Okuda M, Murakami J, Hamabata T, Iwatsuki-Horimoto K, Nakajima H, Mitsuya H, Omagari N, Sugaya N, Yotsuyanagi H, Kawaoka Y. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinialMedicine. 32:100734, 2021. |
| 20. Maeda K, Amano M, Uemura Y, Tsuchiya K, Matsushima T, Noda K, Shimizu Y, Fujiwara A, Takamatsu Y, Ichikawa Y, Nishimura H, Kinoshita M, Matsumoto S, Gatanaga H, Yoshimura K, Oka SI, Mikami A, Sugiura W, Sato T, Yoshida T, Shimada S, Mitsuya H. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. Scientific Reports. 2021. |
| 21. Tanaka A, Yamamoto S, Miyo K, Mizoue T, Maeda K, Sugiura W, Mitsuya H, Sugiyama H, Norio Ohmagari. Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan. Journal of Infection. 82(4):e1-e3, 2021. |
| 22. Maeda K, Higashi-Kuwata N, Kinoshita N, Kutsuna S, Tsuchiya K, Hattori SI, Matsuda K, Takamatsu Y, Gatanaga H, Oka S, Sugiyama H, Ohmagari N, Mitsuya H. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Sci Rep. 11(1):5563, 2021. |
| 23. Noda K, Matsuda K, Yagishita S, Maeda K, Akiyama Y, Terada-Hirashima J, Matsushita H, Iwata S, Yamashita K, Atarashi Y, Watanabe S, Ide N, Yoshida T, Ohmagari N, Mitsuya M, Hamada A. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci. Rep. 11(1):5198, 2021. |
| 24. Matsuda K, Takuya Kobayakawa T, Kariya R, Tsuchiya K, Tsuji K, Ishii T, Gatanaga H, Yoshimura K, Okada S, Mitsuya H, Tamamura H, Maeda K. A therapeutic strategy to combat HIV-1 latently infected cells with a combination of latency-reversing agents containing DAG-lactone PKC activators. Front. Microbiol. 12:636276, 2021. |
| 25. Yamamoto S, Maeda K, Matsuda K, Tanaka A, Horii K, Okudera K, Takeuchi JS, Mizoue T, Konishi M, Ozeki M, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study. Clin Infect Dis. 2021. |
| 26. Yamamoto S, Tanaka A, Kobayashi S, Oshiro Y, Ozeki M, Maeda K, Matsuda K, Miyo K, Mizoue T, Sugiura W, Mitsuya H, Sugiyama H, Ohmagari N. Consistency of the results of rapid serological tests for SARS-CoV-2 among healthcare workers in a large national hospital in Tokyo, Japan. Global Health & Medicine. 3(2):90-94, 2021. |
| 27. Yamamoto S, Tanaka A, Oshiro Y, Ishii M, Ishiwari H, Konishi M, Matsuda K, Ozeki M, Miyo K, Maeda K, Mizoue T, Sugiura W, Mitsuya H, Sugiyama H, Ohmagari N. Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan. Journal of Infection. S0163-4453(21)00259-0, 2021. |
| 28. Terada M, KutsunaS, Saito S, Kinoshita N, Shimanishi Y, Suzuki T, Miyazato Y, Inada M, Nakamoto T, Nomoto H, Ide S, Sato M, Maeda K, Matsunaga A, Satake M, Matsubayashi K, Tsuno H, Kojima M, Kuramistu M, Tezuka K, Ikebe E, Okuma K, Hamaguchi I, Shiratori K, Sato M, Kawakami Y, Inaba K, Igarashi S, Yamauchi R, Matsumura M, Ishimaru K, Cho H, Kuge C, Ishihara M, Gouda M, Tanaka K, Ishizaka Y, Ohmagari N. How we secured a COVID-19 Convalescent Plasma Procurement Scheme in Japan. Transfusion, 10.1111/trf.16541, 2021. |
| 29. Nakajima S, Watashi K, Kato T, Muramatsu M, Wakita T, Tamura N, Hattori SI, Maeda K, Mitsuya H, Yasutake Y, Toyoda T. Biochemical and structural properties of entecavir-resistant hepatitis B virus polymerase with L180M/M204V mutations. J. Virol. 95(16):e0240120, 2021. |
| 30. Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O’Connor SL, O’Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc Natl Acad Sci U S A. 118(27):e2106535118, 2021. |
| 31. Hayashi Y, Tsuchiya K, Yamamoto M, Nemoto-Sasaki Y, Tanigawa K, Hama K, Tanikawa T, Maeda K, Inoue J-I, and Yamashita A. N-(4-Hydroxyphenyl) retinamide suppresses SARS-CoV-2 spike protein-mediated cell-cell fusion and viral infection in vitro. J. Virol. JVI0080721, 2021. |
| 32. Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K, Ito M, Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. J Virol. JVI0155121, 2021. |
| 33. Yasutake Y, Hattori SI, Tamura N, Matsuda K, Kohgo S, Maeda K, Mitsuya H. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine. Sci Rep. 10(1):3021, 2020. |
| 34. Hattori SI, Higshi-Kuwata N, Raghavaiah J, Das D, Bulut H, Davis DA, Takamatsu Y, Matsuda K, Takamune N, Kishimoto N, Okamura T, Misumi S, Yarchoan R, Maeda K, Ghosh AK, Mitsuya H.GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. mBio. 11(4):e01833-20, 2020. |
| 35. Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, Maeda K, Adachi E, Saito M, Nagai H, Ikeuchi K, Ogura T, Baba R, Fujita K, Fukui T, Ito F, Hattori SI, Yamamoto K, Nakamoto T, Furusawa Y, Yasuhara A, Ujie M, Yamada S, Ito M, Mitsuya H, Omagari N, Yotsuyanagi H, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Comparison of rapid antigen tests for COVID-19. Viruses. 12(12):1420, 2020. |
| 36. Nakata H, Maeda K, Das D, Chang SB, Matsuda K, Kalapala Rao KV, Harada S, Yoshimura K, Ghosh AK, and Mitsuya H. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s. Sci. Rep. 9(1)4828, 2019. |
| 37. Matsuda K, Kobayakawa T, Tsuchiya K, Hattori SI, Nomura W, Gatanaga H, Yoshimura K, Oka S, Endo Y, Tamamura H, Mitsuya H, and Maeda K*. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C–induced HIV latency reversal. J. Biol. Chem. 294:116-129, 2019. |
| 38. Iwase, S., Miyazato, P., Katsuya, H., Yang Tan, BJ, Ito, J., Islam, SM, Matsuo, M., Takeuchi, H., Ishida, T., Matsuda, K., Maeda, K., and Satou Y. HIV-1 DNA-capture-seq is a useful tool for the comprehensive characterization of HIV-1 provirus. Sci. Rep. 9(1) :12326, 2019. |
| 39. Maeda, K, Das D., Kobayakawa T., Tamamura H., and Takeuchi, H. Discovery and Development of anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. Curr. Top Med. Chem. 9(18):1621-1649, 2019. |
| 40. Yasutake Y, Hattori S, Hayashi H, Matsuda K, Tamura N, Maeda K, and Mitsuya H. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to an anti-HBV inhibitor, entecavir: structural insights into HBV-RT inhibition by entecavir. Sci Rep. 8:1624, 2018. |
| 41. Takamatsu Y, Das D, Kohgo S, Hayashi H, Delino NS, Sarafianos SG, Mitsuya H, and Maeda K. The high genetic barrier of 4ʹ-ethynyl-2-fluoro-2ʹ-deoxyadenosine (EFdA/MK-8591) stems from strong interactions with the active site of drug-resistant HIV-1 reverse transcriptase. Cell Chem. Biol. S2451-9456(18)30266-6, 2018. |
| 42. Hattori SI*, Matsuda K*, Tsuchiya K, Gatanaga H, Oka S, Yoshimura K, Mitsuya H, and Maeda K. Combination of a latency-reversing agent with a Smac mimetic minimizes secondary HIV-1 infection in vitro. Frontiers in Microbiology. 9:2022, 2018. (* co-first author) |
| 43. Davis DA, Mishra S, Anagho HA, Aisabor, AI, Shrestha P, Wang V, Takamatsu Y, Maeda K, Mitsuya H, Zeldis JB, Yarchoan R. Restoration of immune surface molecules in Kaposi sarcoma-associated herpesvirus infected cells by lenalidomide and pomalidomide. Oncotarget. 8:50342-50358, 2017. |
| 44. Takamatsu Y, Tanaka Y, Kohgo S, Murakami S, Singh K, Das D, Venzon DJ, Amano M, Kuwata N, Aoki M, Delino NS, Hayashi S, Takahashi S, Sukenaga Y, Haraguchi K, Sarafianos SG, Maeda K*, and Mitsuya H. 4’-Modified nucleoside analogs: potent inhibitors active against entecavir-resistant HBV. Hepatology 62:1024-1036, 2015. |
| 45. Das D, Maeda K, Hayashi Y, Gavande N, Desai DV, Chang SB, Ghosh AK, Mitsuya H. Insights into the Mechanism of Inhibition of CXCR4: Identification of Piperidinylethanamine Analogs as Anti-HIV-1 Inhibitors. Antimicrob. Agents Chemother. 59:1895-1904, 2015. |
| 46. Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H. EFdA, a Reverse Transcriptase Inhibitor, Potently Blocks HIV-1 Ex Vivo Infection of Langerhans Cells within Epithelium. J Invest Dermatol. 134:1158-1161, 2014. |
| 47. Daniels SI, Soule EE, Davidoff KS, Bernbaum JG, Hu D, Maeda K, Stahl SJ, Naiman NE, Waheed AA, Freed EO, Wingfield P, Yarchoan R, Davis DA. Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide. FASEB J. 28:106-116, 2014. |
| 48. Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H. Delayed emergence of HIV-1 variants resistant to 4′-ethynyl-2-fluoro-2′-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antivir Ther. 19:179-189, 2014. |
| 49. Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H. P2′ benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety. Antimicrob Agents Chemother. 57:4920-4927, 2013. |
| 50. Maeda K, Das D, Nakata H, Mitsuya H. CCR5 Inhibitors: Emergence, Success and Challenges. Expert Opin Emerg Drugs.17:135-145, 2012. |
| 51. Nishizawa R, Nishiyama T, Hisaichi K, Minamoto C, Murota M, Takaoka Y, Nakai H, Tada H, Sagawa K, Shibayama S, Fukushima D, Maeda K, Mitsuya H. Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist. Bioorg Med Chem. 19:4028-4042, 2011. |
| 52. Maeda K, Das D, Mitsuya H. Development of Antiviral Therapeutics for HIV-1 Infection and AIDS. In “HIV/AIDS in the Post-HAART Era: Manifestations, Treatment & Epidemiology” (ed. John C. Hall, Brian J. Hall and Clay J. Cockerell), Shelton, CT: People’s medical Publishing House – USA. Chapter 40, p 900-937. 2011. |
| 53. Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, and Mitsuya H. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors. J. Virol. 83:3059-3068, 2009. |
| 54. Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, Norman R, Hackney L, Takaoka Y, Mitsuya H. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: Insights to mechanism of allosteric inhibition. J. Mol. Biol. 381:956-974, 2008. |
| 55. Nakata H, Steinberg SM, Koh Y, Maeda K, Takaoka Y, Tamamura H, Fujii N, Mitsuya H. Potent synergistic anti-HIV effects using combinations of a CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob. Agents. Chemother. 52:2111-2119, 2008. |
| 56. Hamada A, Sissung T, Price D, Danesi R, Chau C, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut B, Figg W. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin. Cancer Res. 14:3312-3318, 2008. |
| 57. Maeda K, and Mitsuya H. Development of therapeutics for AIDS: Structure-based molecular targeting. Tuberculosis. 87:S31-34, 2007. |
| 58. Ghosh AK, Sridhar PR, Leshchenko S, Hussain AK, Li J, Kovalevsky AY, Walters DE, Wedekind JE, Grum-Tokars V, Das D, Koh Y, Maeda K, Gatanaga H, Weber IT, Mitsuya H. Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance. J Med Chem. 49:5252-5261, 2006. |
| 59. Habashita H, Kokubo M, Hamano S, Hamanaka N, Toda M, Shibayama S, Tada H, Sagawa K, Fukushima D, Maeda K, Mitsuya, H. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists. J Med Chem. 49:4140-52, 2006. |
| 60. Davis DA, Brown CA, Singer KE, Wang V, Kaufman J, Stahl SJ, Wingfield P, Maeda K, Harada S, Yoshimura K, Kosalaraksa P, Mitsuya H, Yarchoan R. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease. Antiviral Res. 72: 89-99, 2006. |
| 61. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, Arnold E, Mitsuya H. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem. 2006, 281:12688-12698, 2006. |
| 62. Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H. Potent Anti-R5-HIV-1 Effects of a CCR5 Antagonist AK602 in a Novel hu-PBMC-Non-Obase-Diabetic-SCID, IL-2R gamma-Chain-Knocked-Out AIDS Mouse Model. J Virol. 79: 2087-2096, 2005. |
| 63. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H. A spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 HIV-1 in vitro. J Virol. 78:8654-8662, 2004. |
| 64. Tamamura H, Koh Y, Ueda S, Sasaki Y, Yamasaki T, Aoki M, Maeda K, Watai Y, Arikuni H, Otaka A, Mitsuya H, Fujii N. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multi-drug resistant HIV-1 strains. J Med Chem. 46:1764-1768, 2003. |
| 65. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 47:3123-3129, 2003. |
| 66. Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, Ghosh AK, Gulnik SV, Erickson JW, Mitsuya H. UIC-94003: a potent protease inhibitor (PI) that inhibits multi-PI-resistant HIV-1 replication in vitro. J Virol. 76:1349-1358, 2002. |
| 67. Miyakawa T, Obaru K, Maeda K, Harada S, Mitsuya H. Identification of amino acid residues critical for LD78 beta (a variant of human macrophage inflammatory protein-1 alpha) binding to CCR5 and inhibition of R5 HIV-1 replication. J Biol Chem. 277:4649-4655, 2002. |
| 68. Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K, Miyakawa T, Aoki M, Fukushima D, Mitsuya H. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem. 276: 35194-35200, 2001. |